Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy
暂无分享,去创建一个
W. Blattner | J. Carr | S. Ajayi | A. Abimiku | N. Ndembi | R. Nowak | Mary-Ann Etiebet | J. Shepherd | M. Charurat | L. Eyzaguirre | Olufunmilayo Y. Elegba | Harry Chang
[1] D. Kuritzkes,et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen , 2012, AIDS.
[2] Huldrych F Günthard,et al. 2011 update of the drug resistance mutations in HIV-1. , 2011, Topics in antiviral medicine.
[3] Wolfgang Preiser,et al. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI‐based regimens in the western cape, South Africa , 2011, Journal of medical virology.
[4] M. Wainberg,et al. A Template-Dependent Dislocation Mechanism Potentiates K65R Reverse Transcriptase Mutation Development in Subtype C Variants of HIV-1 , 2011, PloS one.
[5] I. Adewole,et al. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. , 2011, AIDS research and human retroviruses.
[6] P. Kaleebu,et al. Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring , 2010, Journal of acquired immune deficiency syndromes.
[7] R. Diaz,et al. HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil. , 2010, AIDS research and human retroviruses.
[8] C. Collins,et al. Can we treat our way out of HIV? , 2010, AIDS research and human retroviruses.
[9] V. Calvez,et al. International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase , 2010, Antimicrobial Agents and Chemotherapy.
[10] B. Brenner,et al. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. , 2009, HIV therapy.
[11] E. Ekong,et al. Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria , 2009, Journal of acquired immune deficiency syndromes.
[12] B. Clotet,et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. , 2009, The Journal of infectious diseases.
[13] R. Schooley,et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] N. Parkin,et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.
[15] M. Wainberg,et al. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens , 2009, Journal of the International AIDS Society.
[16] H. Gunthard,et al. Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[17] A. Calmy,et al. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières , 2008, AIDS.
[18] E. Delaporte,et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. , 2008, AIDS research and human retroviruses.
[19] K. Ruxrungtham,et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV‐infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors , 2007, HIV medicine.
[20] V. DeGruttola,et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.
[21] D. Ngare,et al. Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya , 2007, Journal of acquired immune deficiency syndromes.
[22] Kimberly C. Brouwer,et al. First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border. , 2007, AIDS research and human retroviruses.
[23] Wasun Chantratita,et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] M. D. Miller,et al. In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine , 2006, Antimicrobial Agents and Chemotherapy.
[25] J. Mellors,et al. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. , 2006, The Journal of infectious diseases.
[26] Maurizio Zazzi,et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. , 2006, The Journal of infectious diseases.
[27] Laura Galli,et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.
[28] Lynn Morris,et al. Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent , 2006, Antimicrobial Agents and Chemotherapy.
[29] S. Swaminathan,et al. The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations , 2006, Antiviral therapy.
[30] Lynn Morris,et al. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.
[31] V. Soriano,et al. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations , 2004, AIDS.
[32] M. Wainberg,et al. Resistance Issues With New Nucleoside/Nucleotide Backbone Options , 2004, Journal of acquired immune deficiency syndromes.
[33] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[34] M. Wulfsohn,et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. , 2004, The Journal of infectious diseases.
[35] V. Calvez,et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure , 2004, Journal of medical virology.
[36] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[37] R. Schooley,et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.
[38] M. Peeters,et al. Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. , 2000, AIDS research and human retroviruses.
[39] J. Carr,et al. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. , 1999, Virology.
[40] K. Lole,et al. Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination , 1999, Journal of Virology.
[41] M. Wainberg,et al. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. , 1994, The Journal of biological chemistry.
[42] W. Saxinger,et al. Subgroup G HIV type 1 isolates from Nigeria. , 1994, AIDS research and human retroviruses.
[43] N. Saitou,et al. The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.
[44] M. Kimura. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences , 1980, Journal of Molecular Evolution.
[45] P. Kaleebu,et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. , 2010, The Journal of infectious diseases.
[46] Journal of the International AIDS Society , 2009 .
[47] Tommy F. Liu,et al. Surfing The Web: Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation , 2006 .
[48] C. Allers,et al. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .
[49] Michael D Miller,et al. K65R, TAMs and tenofovir. , 2004, AIDS reviews.
[50] G. Odaibo,et al. 2001 HIV / syphilis sero prevalence and STD syndromes sentinel survey among PTB and STD patients in Nigeria. Technical report. , 2001 .